Harvest Declares Big Pharma Split Corp. February 2026 Distribution
OAKVILLE, Ontario–(BUSINESS WIRE)–Harvest Portfolios Group Inc. (“Harvest”) declares the monthly cash distribution payable for Big Pharma Split Corp.... Read more.
Harvest Announces ETF Name Change for MSTE:TSX
OAKVILLE, Ontario–(BUSINESS WIRE)–Harvest Portfolios Group Inc. (“Harvest”) is pleased to announce that Harvest MicroStrategy Enhanced High Income... Read more.
Harvest ETFs Announces February 2026 Distributions
OAKVILLE, Ontario–(BUSINESS WIRE)–Harvest Portfolios Group Inc. (“Harvest”) announces the following monthly distributions for Harvest ETFs in the... Read more.
Harvest High Income Shares ETFs Announces February 2026 Distributions
OAKVILLE, Ontario–(BUSINESS WIRE)–Harvest Portfolios Group Inc. (“Harvest”) announces the following distributions for Harvest High Income Shares... Read more.
Enphase Energy, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – ENPH
LOS ANGELES–(BUSINESS WIRE)–The DJS Law Group reminds investors of a class action lawsuit against Enphase Energy, Inc. (“Enphase” or “the Company”)... Read more.
Ranger Energy Services, Inc. Announces Date for Fourth Quarter and Full Year 2025 Earnings Conference Call
HOUSTON–(BUSINESS WIRE)–Ranger Energy Services, Inc. (NYSE:RNGR) (the “Company”) will report fourth quarter and full year 2025 financial and operating... Read more.
Mitel and L-SPARK Celebrate Cohort Success at Unified Communications Accelerator Showcase
OTTAWA, Ontario–(BUSINESS WIRE)–Mitel, a global leader in business communications, and L-SPARK, Canada’s leading software accelerator, announced... Read more.
Palladyne AI Announces Fourth Quarter and Full Year Fiscal 2025 Financial Results Conference Call and Webcast
SALT LAKE CITY–(BUSINESS WIRE)–Palladyne AI Corp. (NASDAQ: PDYN and PDYNW) (“Palladyne AI”), a U.S.-based defense and industrial technology company... Read more.
Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed... Read more.
CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
CALQUENCE plus venetoclax demonstrated statistically significant and clinically meaningful improvement in progression-free survival vs. chemoimmunotherapy, with... Read more.